@MAIABiotech MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. posts on X about $maia, data, ceo, strong the most. They currently have [---] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.
Engagements: [--] #
- [--] Week [---] -78%
- [--] Month [-----] +12%
- [--] Months [------] +12%
- [--] Year [------] -54%
Mentions: [--] #
- [--] Week [--] -47%
- [--] Month [--] +457%
- [--] Months [--] +12%
- [--] Year [--] -2.30%
Followers: [---] #
- [--] Week [---] +0.33%
- [--] Month [---] +3.10%
- [--] Months [---] +11%
- [--] Year [---] +18%
CreatorRank: undefined #
Social Influence
Social category influence stocks 99.1% finance 10.81% countries 3.6% travel destinations 1.8% exchanges 0.9%
Social topic influence $maia #4, data 15.32%, ceo 13.51%, strong 4.5%, in the 3.6%, investment 1.8%, the first 1.8%, $ne 1.8%, capital markets 1.8%, growth 1.8%
Top accounts mentioned or mentioned by @benzinga @asco @iaslc @aacrncieortc @aacr @nationwidekids @biospace @oncologycompasss @iambiotech @ascos @cromospharma @ascopost @cancernetwrk @nyse @sabrinaserani @targetedonc @biobosspodcast @myesmo @febsnews @cellsmdpi
Top assets mentioned MAIA Biotechnology, Inc. (MAIA) Noble Corporation (NE)
Top Social Posts
Top posts by engagements in the last [--] hours
"MAIA highlights progress and priorities for [----] including FDA Fast Track designation for ateganosine in NSCLC and concurrent Phase 2/3 trials advancing toward key clinical milestones. Read more here: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"
X Link 2026-01-20T16:33Z [---] followers, [---] engagements
"MAIA to initiate new digital asset treasury strategy focused on top-tier #cryptocurrency assets diversifying our investment portfolio with leading and dynamic #crypto tokens in the rapidly evolving #blockchain space. Read the press release: $MAIA https://bit.ly/4o3y50p https://bit.ly/4o3y50p"
X Link 2025-10-07T14:37Z [---] followers, [----] engagements
"MAIA recently presented a Trial in Progress poster at the [----] @AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Read the press release for more insight on the poster: $MAIA #Targets25 #Oncology #Biotech https://bit.ly/47bS7k0 https://bit.ly/47bS7k0"
X Link 2025-10-27T16:22Z [---] followers, [---] engagements
"MAIA Biotechnology shared updates on its THIO-101 Phase [--] trial at the [----] AACR-NCI-EORTC Conference marking progress in enrollment and international site expansion across Taiwan and Turkey. ICYMI: $MAIA #Targets25 #Oncology #Biotech https://bit.ly/47bS7k0 https://bit.ly/47bS7k0"
X Link 2025-11-04T14:30Z [---] followers, [---] engagements
"MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romanias [----] Smart Diaspora Conference on Oncology Research and Innovation. Read the press release: $MAIA #Oncology #NSCLC https://bit.ly/4pl67y0 https://bit.ly/4pl67y0"
X Link 2025-11-20T15:08Z [---] followers, [---] engagements
"MAIA highlights ongoing momentum of ateganosine clinical program at #SITC2025. The posters focus on the ongoing Phase [--] THIO-101 expansion and Phase [--] THIO-104 clinical trials of its first-in-class ateganosine treatment for #NSCLC. Read more: $MAIA https://bit.ly/3XG3ta6 https://bit.ly/3XG3ta6"
X Link 2025-11-21T14:32Z [---] followers, [---] engagements
"MAIA Biotechnology to begin screening patients in Romania for the expansion phase of its THIO-101 Phase [--] clinical trial. CEO Dr. Vlad Vitoc comments that this expansion is rewarding for several reasons. Read the release: $MAIA #Biotech #NSCLC https://bit.ly/4pl67y0 https://bit.ly/4pl67y0"
X Link 2025-11-25T15:00Z [---] followers, [---] engagements
"It was a privilege to return to #SITC2025 and highlight Phase [--] THIO-101 and Phase [--] THIO-104 clinical trials of our first-in-class small molecule telomere targeting agent ateganosine as a treatment for #NSCLC. $MAIA https://bit.ly/3XG3ta6 https://bit.ly/3XG3ta6"
X Link 2025-12-01T15:00Z [---] followers, [---] engagements
"MAIA Biotechnology Announces Open Market Purchases by CEO and Directors. Read the press release: $MAIA https://bit.ly/48AmY9s https://bit.ly/48AmY9s"
X Link 2025-12-01T16:51Z [---] followers, [---] engagements
"MAIA is targeting the $50B immunotherapy market's gap: advanced NSCLC patients who are CPI/chemo-refractory. Ateganosine our telomere-targeting agent is a novel pathway for this population. Phase [--] THIO-104 initiated after FDA Fast Track. $MAIA https://bit.ly/4q6zNzs https://bit.ly/4q6zNzs"
X Link 2025-12-10T19:28Z [---] followers, [---] engagements
"MAIA achieves a key milestone the first patient dosed in the THIO-104 phase [--] pivotal trial. This trial evaluates ateganosine sequenced with a CPI as a third-line treatment for advanced NSCLC patients who are CPI/chemo-resistant. Read the release: $MAIA https://bit.ly/4prIy77 https://bit.ly/4prIy77"
X Link 2025-12-11T15:31Z [---] followers, [---] engagements
"MAIAs emerging clinical results continue to surpass expectations. Ateganosine advances toward Phase [--] as the only direct telomere-targeting anticancer agent currently in clinical development anywhere. Full release: $MAIA https://bit.ly/48J7UpW https://bit.ly/48J7UpW"
X Link 2025-12-11T19:20Z [---] followers, [---] engagements
"In case you missed it: MAIA's Phase [--] program reached a key milestone with the first patient dosed in our pivotal trial. Progress towards FDA approval underway. Details: $MAIA https://bit.ly/4prIy77 https://bit.ly/4prIy77"
X Link 2025-12-18T18:00Z [---] followers, [---] engagements
"MAIA's ateganosine is a first-in-class telomere-targeting agent that exploits a universal cancer feature. Its dual mechanism triggers cancer cell death and activates immune response. Phase [--] THIO-104 has begun under FDA Fast Track. Full release: $MAIA https://bit.ly/48J7UpW https://bit.ly/48J7UpW"
X Link 2025-12-22T14:00Z [---] followers, [---] engagements
"The $34.1B NSCLC market projected to double is ready for disruption. $MAIA is positioned with ateganosine to capture value in the CPI-refractory population. Commercial opportunity spans Glioblastoma HCC and SCLC backed by FDA ODDs. View our strategy: https://bit.ly/4q6zNzs https://bit.ly/4q6zNzs"
X Link 2025-12-23T14:00Z [---] followers, [---] engagements
"MAIAs leadership continues to demonstrate a unified stance. Recent insider buying in [----] demonstrates confidence in the companys strategy ateganosines growing body of clinical evidence and the opportunity ahead. ICYMI: $MAIA https://bit.ly/4a5p1od https://bit.ly/4a5p1od"
X Link 2025-12-26T14:00Z [---] followers, [----] engagements
"First patient dosed in THIO-104 MAIAs pivotal Phase [--] trial for ateganosine in third-line NSCLC. FDA Fast Track designated; global enrollment active. Get the details: $MAIA https://bit.ly/4prIy77 https://bit.ly/4prIy77"
X Link 2025-12-29T14:00Z [---] followers, [----] engagements
"Only telomere-targeting agent in clinical development: ateganosine begins pivotal Phase [--] trial for advanced NSCLC with statistical models showing high probability of technical success for regulatory approval. $MAIA https://bit.ly/48J7UpW https://bit.ly/48J7UpW"
X Link 2026-01-05T14:00Z [---] followers, [----] engagements
"Ateganosine remains the only direct telomere-targeting therapy in clinical development for NSCLC. MAIA continues to leverage its differentiated approach while preparing second-generation molecules for clinical evaluation. Learn more: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"
X Link 2026-01-23T15:00Z [---] followers, [----] engagements
"Late-stage clinical development continues at MAIA. Ateganosine is advancing through a pivotal Phase [--] trial alongside an expanded Phase [--] study in NSCLC with multiple data readouts expected to inform next regulatory steps. Learn more: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"
X Link 2026-01-26T15:00Z [---] followers, [----] engagements
"FDA Fast Track designation remains a key part of MAIAs ateganosine strategy enabling continued dialogue as late-stage clinical trials progress. Details: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"
X Link 2026-01-29T15:00Z [---] followers, [----] engagements
"On #WorldCancerDay we recognize the patients and families affected by cancer. MAIAs ateganosine is an investigational therapy in late-stage trials for NSCLC. Learn more: $MAIA https://maiabiotech.com/pipeline/thio/ https://maiabiotech.com/pipeline/thio/"
X Link 2026-02-04T15:19Z [---] followers, [---] engagements
"MAIA Biotech Completes Enrollment For Phase [--] Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer. Read more via @Benzinga here: $MAIA #Oncology #Biotech #NSCLC #Research https://bit.ly/42Xvf3V https://bit.ly/42Xvf3V"
X Link 2024-02-28T14:50Z [---] followers, [---] engagements
"Yesterday MAIA welcomed immuno-oncology leader Dr. Remus Vezan to our SAB. Dr. Vezans vast #oncology experience played an instrumental role in FDA approval and commercialization of multiple blockbuster products. Read: $MAIA #OncNews #Pharma #Healthcare https://bit.ly/42SZh90 https://bit.ly/42SZh90"
X Link 2024-02-28T16:56Z [---] followers, [---] engagements
"MAIA recently completed enrollment for the phase [--] trial of its telomere targeting agent THIO to fight #NSCLC. Learn more about the development here: $MAIA #Oncology #Biotech #ClinicalTrials https://bit.ly/42Xvf3V https://bit.ly/42Xvf3V"
X Link 2024-02-29T14:45Z [---] followers, [---] engagements
"MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients. Read the press release here: $MAIA #NSCLC #Biotech #Research https://bit.ly/4a2S3RV https://bit.ly/4a2S3RV"
X Link 2024-03-06T15:15Z [---] followers, [---] engagements
"MAIA Biotechnology and Nationwide Childrens Hospital Announce Presentation of THIOs Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting. Read the press release: $MAIA @AACR @nationwidekids #AACR2024 #AACR24 #DIPG https://bit.ly/4c7h0Of https://bit.ly/4c7h0Of"
X Link 2024-03-06T16:48Z [---] followers, [---] engagements
"Today MAIA announced that combination of THIO 180mg + cemiplimab achieved 38% ORR in difficult-to-treat third-line #NSCLC exceeding the current standard of care. Dive into the positive efficacy data here: $MAIA #OncNews #Biotech https://bit.ly/4a2S3RV https://bit.ly/4a2S3RV"
X Link 2024-03-06T20:54Z [---] followers, [---] engagements
"ORR of 38% significantly exceeds the current standard of care in #NSCLC third-line patients. Discover how MAIA is demonstrating the potential of THIO in recently released positive efficacy data here: $MAIA #OncNews #Biotech https://ir.maiabiotech.com/news-events/press-releases/detail/94/maia-biotechnology-announces-strong-efficacy-of-thio-as https://ir.maiabiotech.com/news-events/press-releases/detail/94/maia-biotechnology-announces-strong-efficacy-of-thio-as"
X Link 2024-03-08T14:30Z [---] followers, [---] engagements
"Our second-generation telomere targeting program is engaged in research and development for new drugs derived from THIO. Read further into the preclinical studies that have shown highly significant anti-cancer efficacy here: $MAIA #Immunotherapy #Oncology https://bit.ly/3Tk7f7M https://bit.ly/3Tk7f7M"
X Link 2024-03-08T16:30Z [---] followers, [---] engagements
"Indications for treatment with THIO include #NSCLC and glioblastoma the most aggressive and most common type of brain cancer. Dive into THIOs potent anticancer activity updates here: $MAIA #Oncology #GBM https://bit.ly/3Tk7f7M https://bit.ly/3Tk7f7M"
X Link 2024-03-11T13:45Z [---] followers, [---] engagements
"(1/6) MAIAs Director Ngar Louie continues to invest capital in the company as we continue to build upon research and development for our cancer treatments' telomere-targeting program THIO. Read more on the investment here: $MAIA https://yhoo.it/3Tqdupx https://yhoo.it/3Tqdupx"
X Link 2024-03-21T13:33Z [---] followers, [----] engagements
"MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to Its Scientific Advisory Board. Read the press release here: $MAIA #Biotech #BusinessUpdate https://ir.maiabiotech.com/news-events/press-releases/detail/97/maia-biotechnology-welcomes-prominent-medical-oncology https://ir.maiabiotech.com/news-events/press-releases/detail/97/maia-biotechnology-welcomes-prominent-medical-oncology"
X Link 2024-03-21T20:07Z [---] followers, [---] engagements
"MAIA Biotechnology Announces Share Purchase by Director Stan Smith PhD in a $2.9 Million Private Placement. Read the press release here: $MAIA #BusinessUpdate https://bit.ly/4ahAgHa https://bit.ly/4ahAgHa"
X Link 2024-03-22T19:14Z [---] followers, [----] engagements
"MAIA Biotechnology Announces $1.33 Million Private Placement. Read the press release here: $MAIA #BusinessUpdate https://bit.ly/3Tt0SxU https://bit.ly/3Tt0SxU"
X Link 2024-03-26T15:45Z [---] followers, [---] engagements
"MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero. Read the press release here: $MAIA https://bit.ly/3TF759Y https://bit.ly/3TF759Y"
X Link 2024-03-28T19:33Z [---] followers, [----] engagements
"MAIA Biotechnology to Present at Two Investor Conferences in April [----]. Read the press release here: $MAIA #Conference #BusinessUpdate https://bit.ly/3xoKya9 https://bit.ly/3xoKya9"
X Link 2024-04-05T13:57Z [---] followers, [----] engagements
"CEO Vlad Vitoc M.D. is presenting the 14th Annual LD Micro Invitational tomorrow April [--] at 4:30PM ET in #NYC. #Conference virtual registration and 1x1 meeting details available here: $MAIA https://bit.ly/3xoKya9 https://bit.ly/3xoKya9"
X Link 2024-04-08T17:36Z [---] followers, [---] engagements
"In a recent @BioSpace piece MAIA CEO Vlad Vitoc lauded successful recent Phase III trial successes as welcome advancements noting that they will improve care options for patients beyond what is currently available. Read the full article: $MAIA #OncNews https://bit.ly/4d2yFan https://bit.ly/4d2yFan"
X Link 2024-04-08T19:00Z [---] followers, [---] engagements
"Today at 4:30PM ET CEO Vlad Vitoc M.D. is presenting the 14th Annual LD Micro Invitational. #Conference virtual registration and 1x1 meeting details available here: $MAIA https://bit.ly/3xoKya9 https://bit.ly/3xoKya9"
X Link 2024-04-09T14:00Z [---] followers, [---] engagements
"CEO Vlad Vitoc was featured in @OncologyCompasss April Issue to discuss our cancer telomere targeting agent THIO ongoing phase [--] trial data evaluating THIO-101 in patients with #NSCLC 100% DCR in 2nd line and more. Dive into how THIO works here: $MAIA https://bit.ly/43ZqnMg https://bit.ly/43ZqnMg"
X Link 2024-04-10T13:15Z [---] followers, [---] engagements
"CEO Vlad Vitoc M.D. is presenting at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April [--] at 11:00AM ET. Details for registration and 1x1 meetings are available here: $MAIA #BusinessUpdate https://bit.ly/3xoKya9 https://bit.ly/3xoKya9"
X Link 2024-04-15T17:07Z [---] followers, [---] engagements
"Today at 11:00AM ET CEO Vlad Vitoc M.D. is presenting at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. Details for registration and 1x1 meetings are available here: $MAIA #BusinessUpdate https://bit.ly/3xoKya9 https://bit.ly/3xoKya9"
X Link 2024-04-17T13:00Z [---] followers, [---] engagements
"MAIA Biotechnology Announces $1.0 Million Private Placement. Read the press release here: $MAIA https://bit.ly/4dajuvC https://bit.ly/4dajuvC"
X Link 2024-04-23T17:59Z [---] followers, [---] engagements
"MAIA Biotechnology Announces Share Purchase by Director Stan Smith Ph.D. in Private Placement. Read the press release here: $MAIA https://bit.ly/3WfPg4o https://bit.ly/3WfPg4o"
X Link 2024-04-29T17:55Z [---] followers, [----] engagements
"MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement. Read the press release here: $MAIA https://bit.ly/3UdyeBi https://bit.ly/3UdyeBi"
X Link 2024-04-30T14:30Z [---] followers, [---] engagements
"MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) [----] Annual Meeting. Read the press release here: $MAIA @ASCO #ASCO24 #NSCLC https://bit.ly/4dL9ngY https://bit.ly/4dL9ngY"
X Link 2024-05-16T14:05Z [---] followers, [---] engagements
"Today MAIA announced that an abstract about its Phase [--] THIO-101 clinical trial was accepted for poster presentation at the #ASCO24 Annual Meeting scheduled for presentation on June [--] from 1:30pm to 4:30pm CST. Details: $MAIA @ASCO #NSCLC https://bit.ly/4dL9ngY https://bit.ly/4dL9ngY"
X Link 2024-05-16T16:00Z [---] followers, [---] engagements
"MAIA Biotechnology to Present at the BIO International Convention [----]. Read the press release here: $MAIA @IAmBiotech #BIO2024 https://bit.ly/3wLD0hy https://bit.ly/3wLD0hy"
X Link 2024-05-17T14:09Z [---] followers, [---] engagements
"MAIAs Unique Telomere Targeting Agent Currently In #Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market. Dive into the article via @Benzinga here: $MAIA https://bit.ly/3K9eUk0 https://bit.ly/3K9eUk0"
X Link 2024-05-21T14:27Z [---] followers, [---] engagements
"Schedule a meeting with our CEO Dr. Vitoc at #BIO2024 to learn more about THIO our telomere-targeting agent in development for cancer drug discovery and treatment. He will also present up-to-date findings from the Phase [--] THIO-101 clinical trial: $MAIA https://bit.ly/2EJf14t https://bit.ly/2EJf14t"
X Link 2024-05-21T14:59Z [---] followers, [---] engagements
"Discover how MAIA's groundbreaking telomere targeting agent in clinical development is revolutionizing the billion-dollar cancer therapy market. More insights in this new @Benzinga aritcle: $MAIA https://bit.ly/3K9eUk0 https://bit.ly/3K9eUk0"
X Link 2024-05-22T13:30Z [---] followers, [---] engagements
"MAIA will be presenting a poster at #ASCO24 on 6/3 at 1:30pm CT revealing new efficacy data from our Phase [--] THIO-101 trial in #NSCLC. The abstract will also be available online the week prior via @ASCOs website. Details: $MAIA https://bit.ly/4dL9ngY https://bit.ly/4dL9ngY"
X Link 2024-05-22T15:57Z [---] followers, [---] engagements
"Dr. Vitocs presentation at #BIO2024 highlighting our Phase [--] THIO-101 #clinicaltrial is scheduled for 6/5 at 11:30am PT in Theater [--]. He will also be available for meetings. Interested parties can submit a request here: $MAIA https://bit.ly/2EJf14tb https://bit.ly/2EJf14tb"
X Link 2024-05-23T14:52Z [---] followers, [---] engagements
"MAIA looks forward to revealing the newest efficacy results from THIO-101 and discussing our pioneering telomere targeting science underlying THIO. Our poster will be presented on 6/3 at 1:30pm CT. More information here: https://bit.ly/4dL9ngY https://bit.ly/4dL9ngY"
X Link 2024-05-29T15:40Z [---] followers, [----] engagements
"CEO Vlad Vitoc M.D. will deliver a presentation at #BIO2024 on 6/5 at 11:30am PT featuring up-to-date findings from our Phase [--] THIO-101 #clinicaltrial evaluating THIO sequenced with the immune CPI cemiplimab (Libtayo) in advanced #NSCLC. More: $MAIA https://bit.ly/3wLD0hy https://bit.ly/3wLD0hy"
X Link 2024-05-30T15:00Z [---] followers, [---] engagements
"#ASCO24 has begun The MAIA team is having a productive first day and our CEO Vlad Vitoc is holding meetings with KOLs. Make sure to stop by our poster presentation in the #NSCLC Metastatic session on Monday 6/3 1:30 - 4:30pm CT in Hall A at Board [---] - Abstract [----]. $MAIA"
X Link 2024-05-31T20:04Z [---] followers, [----] engagements
"Today at 1:30pm CT MAIAs poster presentation revealing new efficacy data from Phase [--] THIO-101 trial in #NSCLC will be presented at #ASCO24. It is also available on our website here: $MAIA https://bit.ly/4bI0wuC https://bit.ly/4bI0wuC"
X Link 2024-06-03T13:30Z [---] followers, [----] engagements
"Don't miss our poster presentation today at 1:30pm CT at #ASCO24 Board [---] Abstract [----] We're looking forward to sharing the latest data from our Phase [--] THIO-101 clinical trial for patients with advanced #NSCLC. See you there Details: $MAIA https://bit.ly/4dL9ngY https://bit.ly/4dL9ngY"
X Link 2024-06-03T16:22Z [---] followers, [----] engagements
"MAIA Biotechnology Reveals New #Clinical Data Showing THIOs Strong Efficacy in Non-Small Cell Lung Cancer. Read the press release here: $MAIA #NSCLC #Oncology #ASCO24 https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"
X Link 2024-06-04T15:15Z [---] followers, [----] engagements
"Today at 11:30am PT Dr. Vitoc is presenting at #BIO2024 to highlight findings from MAIAs Phase [--] THIO-101 clinical trial evaluating THIO our telomere-targeting agent in #NSCLC patients. Hope to see you there $MAIA"
X Link 2024-06-05T13:30Z [---] followers, [----] engagements
"MAIA announced new efficacy data from our Phase [--] THIO-101 #clinicaltrial evaluating THIO in patients with #NSCLC greatly surpassing the standard-of-care with ORR of 38% and DCR of 85% in third-line treatment. Dive into the press release: $MAIA #ASCO24 https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"
X Link 2024-06-05T13:45Z [---] followers, [----] engagements
"New efficacy data from MAIAs Phase [--] THIO-101 #clinicaltrial in patients with advanced #NSCLC shows an ORR of 38% and a DCR of 85% exceeding the current standard-of-care in third-line treatment. Read the press release here: $MAIA #Oncology #ASCO24 https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"
X Link 2024-06-06T13:30Z [---] followers, [---] engagements
"MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent. Read the press release here: $MAIA #Biopharma #NSCLC #Immunotherapy https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"
X Link 2024-06-06T14:14Z [---] followers, 10.8K engagements
"New from @Benzinga: New Clinical Data Reveals MAIA Biotechnologys THIO Achieves High Efficacy In Advanced #NSCLC Treatment. Dive into the article here: $MAIA #Biotech #Immunotherapies https://bit.ly/3XbgXfe https://bit.ly/3XbgXfe"
X Link 2024-06-06T15:07Z [---] followers, [---] engagements
"Today MAIA announced key achievements year-to-date including recent #clinical progress for lead candidate THIO a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in #NSCLC. Read: $MAIA https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"
X Link 2024-06-06T15:57Z [---] followers, [----] engagements
"New clinical data shows THIOs strong efficacy in #NSCLC patients with ORR of 38% and DCR of 85% in third-line treatment surpassing the current standard-of-care. Read MAIAs press release for highlights on the results: $MAIA #ClinicalResearch #Oncology https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"
X Link 2024-06-07T13:30Z [---] followers, [---] engagements
"MAIAs newest data shows THIOs strong outperformance against standard-of-care treatments in #NSCLC. THIO-101 clinical data showed: ORR of 38% DCR of 85% Dive into the press release: $MAIA #ClinicalResearch #CancerResearch https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"
X Link 2024-06-07T16:27Z [---] followers, [---] engagements
"Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable By Fdas Approval Of A Telomerase Inhibitor Agent Therapy. Read the press release here: $MAIA #Biopharma #CancerResearch https://bit.ly/4aR8Wz9 https://bit.ly/4aR8Wz9"
X Link 2024-06-07T16:54Z [---] followers, [----] engagements
"MAIA is developing telomere-targeting #immunotherapies for cancer treatment. Recent promising new clinical data has unveiled efficacy of our lead product candidate THIO in treating #NSCLC. Read more about our key findings here: $MAIA #Oncology https://bit.ly/3XbgXfe https://bit.ly/3XbgXfe"
X Link 2024-06-07T17:45Z [---] followers, [---] engagements
"Our most recent #clinical data points to THIOs unprecedented DCR of 85% ORR of 38% and post-therapy patient benefits. Third-line treatment with THIO has far outperformed reported standard-of-care data in #NSCLC. Read our latest news: $MAIA #Oncology https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"
X Link 2024-06-10T13:30Z [---] followers, [----] engagements
"MAIA and @CromosPharma are part of an innovative collaboration to advance cancer treatment focused on THIO a groundbreaking telomere-targeting agent for #NSCLC. Read the news here: $MAIA #ASCO2024 https://bit.ly/3XAFUkg https://bit.ly/3XAFUkg"
X Link 2024-06-24T17:12Z [---] followers, [----] engagements
"Pleased to share that Dr. Jankowski the presenting author of MAIAs poster at #ASCO24 and key investigator in our Phase [--] #clinicaltrial was selected as one of the very few authors to provide a video update. Watch his discussion via @ASCOPost: $MAIA https://bit.ly/3RExJja https://bit.ly/3RExJja"
X Link 2024-06-25T15:51Z [---] followers, [---] engagements
"#ASCO24 recap MAIA had a productive time networking exploring exhibits and presenting new clinical data in a poster session showing THIOs strong efficacy in #NSCLC. Watch below. $MAIA"
X Link 2024-06-26T13:30Z [---] followers, [----] engagements
"Discover new efficacy data from MAIAs Phase [--] THIO-101 #clinicaltrial evaluating THIO sequenced with the immune CPI cemiplimab (Libtayo) in patients with advanced #NSCLC: $MAIA https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"
X Link 2024-07-10T13:15Z [---] followers, [----] engagements
"MAIA Biotechnology Announces New Updates from Phase [--] Trial of Novel Cancer Treatment Agent. Read the press release here: $MAIA #Biopharma #NSCLC #Immunotherapy https://bit.ly/4cP1AOD https://bit.ly/4cP1AOD"
X Link 2024-07-23T13:36Z [---] followers, [----] engagements
"MAIA announced positive treatment updates from its Phase [--] clinical trial THIO-101 evaluating THIO in patients with advanced #NSCLC. Read the press release here: $MAIA #Biotech #ClinicalResearch https://bit.ly/4cP1AOD https://bit.ly/4cP1AOD"
X Link 2024-07-24T13:45Z [---] followers, [---] engagements
"Telomere-Targeting Agent Demonstrates Tolerability in Advanced #NSCLC. Read more about our latest news via @CancerNetwrk here: $MAIA #Biotechnology https://bit.ly/3A5nb6D https://bit.ly/3A5nb6D"
X Link 2024-07-24T15:46Z [---] followers, [---] engagements
"Ongoing benefits of THIO in longer-term patients are particularly notable signifying THIOs potential as a durable and efficacious treatment for advanced #NSCLC patients. Read the latest clinical updates from our Phase [--] #clinicaltrial of THIO-101: $MAIA https://bit.ly/4cP1AOD https://bit.ly/4cP1AOD"
X Link 2024-07-25T13:45Z [---] followers, [----] engagements
"#ICYMI: MAIA recently released key achievements year-to-date including #clinical progress for lead candidate THIO a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in #NSCLC. Read more: $MAIA https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"
X Link 2024-07-26T14:05Z [---] followers, [---] engagements
"#OnThisDay two years ago MAIA listed on the @NYSE. This milestone reflects our dedication to #clinicalresearch for our lead candidate in development THIO a telomere targeting agent that has shown exceptional efficacy on patients in NSCLC. $MAIA #NYSE #Biotech #Innovation"
X Link 2024-07-28T17:19Z [---] followers, [----] engagements
"MAIAs recent #clinical data points to THIOs unprecedented DCR of 85% ORR of 38% and post-therapy patient benefits. Third-line treatment with THIO has far outperformed reported standard-of-care data in #NSCLC. If you missed it read here: $MAIA https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"
X Link 2024-07-31T13:22Z [---] followers, [---] engagements
"THIO Shows Lower Toxicity Than Standard Treatments in #NSCLC Study. Read more about our phase [--] trial that shows the treatment has been well-tolerated and demonstrates lower rates of toxicity by @sabrinaserani via @TargetedOnc here: $MAIA #Biotechnology https://bit.ly/3SrI4PR https://bit.ly/3SrI4PR"
X Link 2024-08-01T13:30Z [---] followers, [----] engagements
"MAIA CEO Vlad Vitoc shares his insights with @BioBossPodcast about leadership in #biopharma and how MAIA is working to develop and deliver innovative medicines to improve and extend the lives of people living with cancer. Tune in: $MAIA #Biotech #Oncology https://bit.ly/4kjJUhY https://bit.ly/4kjJUhY"
X Link 2025-03-03T16:30Z [---] followers, [---] engagements
"MAIA Biotechnology Receives USAN Council Approval for Ateganosine as Nonproprietary (Generic) Name for Anticancer Agent THIO. Read the press release here: $MAIA #Biotech #NSCLC https://bit.ly/43YNsAz https://bit.ly/43YNsAz"
X Link 2025-03-19T15:35Z [---] followers, [---] engagements
"MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress (ELCC) [----]. Read the press release here: $MAIA @myESMO #ELCC25 https://bit.ly/4cbQwvq https://bit.ly/4cbQwvq"
X Link 2025-03-25T14:32Z [---] followers, [---] engagements
"MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in [----] Letter to Shareholders. Read the press release here: $MAIA #Biotech #NSCLC https://bit.ly/4iQiX4D https://bit.ly/4iQiX4D"
X Link 2025-04-01T13:56Z [---] followers, [---] engagements
"MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (@ASCO) [----] Annual Meeting. Read the press release: $MAIA #Oncology #Biotech #ASCO25 https://bit.ly/3S6aEpr https://bit.ly/3S6aEpr"
X Link 2025-05-15T21:07Z [---] followers, [---] engagements
"MAIA announces positive efficacy update for Phase [--] THIO-101 #clinicaltrial in #NSCLC. Read the press release: $MAIA #Biotech https://bit.ly/4dNxxrT https://bit.ly/4dNxxrT"
X Link 2025-06-05T13:56Z [---] followers, [---] engagements
"MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase [--] Clinical Trial. Read the press release here: $MAIA #Biotech #NSCLC https://bit.ly/4kTkzLw https://bit.ly/4kTkzLw"
X Link 2025-06-05T15:14Z [---] followers, [---] engagements
"MAIA is pleased to announce a master clinical supply agreement with Roche for hard-to-treat cancer therapies. Read the press release: $MAIA #Immunotherapy #Oncology #Biotech https://bit.ly/43WDFJy https://bit.ly/43WDFJy"
X Link 2025-06-18T14:55Z [---] followers, [---] engagements
"MAIA Biotechnology is pleased to welcome leading #hepatocellularcarcinoma clinician-scientists to its Scientific Advisory Board. Planning for phase [--] #clinicaltrial in HCC underway. Read the press release: $MAIA #Oncology #Biotech https://bit.ly/3ZJxw2h https://bit.ly/3ZJxw2h"
X Link 2025-06-24T14:11Z [---] followers, [---] engagements
"MAIA is planning for a Phase [--] clinical trial in #hepatocellularcarcinoma. With the appointment of our new SAB members they will advise MAIA on designs and protocols for its CST in HCC and may participate in future investigator sponsored trials. $MAIA https://bit.ly/3ZJxw2h https://bit.ly/3ZJxw2h"
X Link 2025-06-26T18:43Z [---] followers, [---] engagements
"MAIA's clinical master supply agreement with Roche supports the evaluation of ateganosine (THIO) in combination with Tecentriq in hard-to-treat cancers. The combination was found to be highly synergistic and effective in #preclinical studies. ICYMI: $MAIA https://bit.ly/3TNcT1F https://bit.ly/3TNcT1F"
X Link 2025-06-30T15:29Z [---] followers, [---] engagements
"MAIA Biotechnology to present two posters featuring cancer telomere-targeting agents at @FEBSnews. Read the press release: $MAIA #FEBSCongress2025 #CancerResearch #Oncology #Biotech https://ir.maiabiotech.com/news-events/press-releases/detail/143/maia-biotechnology-to-present-two-posters-featuring-cancer https://ir.maiabiotech.com/news-events/press-releases/detail/143/maia-biotechnology-to-present-two-posters-featuring-cancer"
X Link 2025-07-01T15:28Z [---] followers, [---] engagements
"MAIA will present two posters at #FEBSCongress2025 featuring our lead telomere-targeting agent and next-generation treatments. Session date and time: July [--] [----] from 12:30pm to 2:30pm TRT. More details are available here: $MAIA #Oncology #Biotech https://bit.ly/4ntzu0N https://bit.ly/4ntzu0N"
X Link 2025-07-03T13:30Z [---] followers, [---] engagements
"MAIA is presenting two posters today at the #FEBS2025Congress Cancer Therapy session 12:30-2:30pm TRT highlighting our lead telomere-targeting agent and next-generation treatments. Poster presentation details available here: $MAIA https://bit.ly/4ntzu0N https://bit.ly/4ntzu0N"
X Link 2025-07-07T07:00Z [---] followers, [---] engagements
"MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase [--] Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer. Read the press release: $MAIA #Biotech #NSCLC https://bit.ly/4nWbgNh https://bit.ly/4nWbgNh"
X Link 2025-07-09T14:04Z [---] followers, [----] engagements
""Ateganosines observed OS in third-line #NSCLC exceeds all known benchmarks. Dr. Vlad Vitoc MAIA CEO. See announcement on our Phase [--] trial expansion: $MAIA #Biotech #Oncology https://bit.ly/4nWbgNh https://bit.ly/4nWbgNh"
X Link 2025-07-17T13:30Z [---] followers, [---] engagements
"MAIA Biotechnology Announced Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy. Read the press release: $MAIA #Biotech #Oncology #ClinicalResearch https://bit.ly/3GQgrgQ https://bit.ly/3GQgrgQ"
X Link 2025-07-17T14:29Z [---] followers, [---] engagements
"MAIA Biotechnology Receives FDAs Fast Track Designation for Ateganosine as a Treatment for #NSCLC. Read the press release: $MAIA #Biotech https://bit.ly/3UvBQPA https://bit.ly/3UvBQPA"
X Link 2025-07-28T13:42Z [---] followers, [---] engagements
"The FDAs Fast Track Designation recognizes ateganosines (THIO) potential as a new therapeutic paradigm in cancer treatment science. Missed the announcement Learn more about our pivotal Phase [--] THIO-101 clinical trial: $MAIA #Biotech https://bit.ly/3UvBQPA https://bit.ly/3UvBQPA"
X Link 2025-07-30T13:30Z [---] followers, [---] engagements
"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy. Read the press release: $MAIA #Immunotherapy #Biotech #Biopharma https://bit.ly/4fzA0Hb https://bit.ly/4fzA0Hb"
X Link 2025-08-13T14:45Z [---] followers, [---] engagements
"MAIA announces publication of interim clinical data detailing developments in its Phase [--] THIO-101 of telomere targeting anticancer agent in peer-reviewed journal @Cells_MDPI. Read the press release: $MAIA #cells_mdpi #CellBiology #Immunotherapy #Biotech https://bit.ly/4lSVssj https://bit.ly/4lSVssj"
X Link 2025-08-27T14:10Z [---] followers, [---] engagements
"MAIAs abstract selected for poster presentation at @IASLC #WCLC25 September [--] in Barcelona Spain. Poster details durability and efficacy of ateganosine (THIO) treatment in NSCLC. Read the press release: $MAIA #LungCancer https://bit.ly/4peqTAc https://bit.ly/4peqTAc"
X Link 2025-09-05T14:34Z [---] followers, [----] engagements
"MAIA is presenting ateganosine (THIO) at @IASLC #WCLC25. đź“Š P1.11 - Metastatic NSCLC Immunotherapy đź“…Sunday September [--] [----] đź•™10:30 a.m. to 12:00 p.m. CEST đź“ŤBarcelona Spain Poster available at Press Release: $MAIA https://bit.ly/4peqTAc https://bit.ly/48dgkFj https://bit.ly/4peqTAc https://bit.ly/48dgkFj"
X Link 2025-09-07T08:00Z [---] followers, [----] engagements
"MAIA highlighted positive efficacy data from its Phase [--] clinical trial THIO-101 evaluating treatment with ateganosine (THIO) sequenced with the immune CPI cemiplimab in patients with advanced #NSCLC. Read the press release: $MAIA #Biotech #OncNews https://bit.ly/46hEQo8 https://bit.ly/46hEQo8"
X Link 2025-09-11T14:44Z [---] followers, [---] engagements
"MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase [--] Trial of Cancer-Fighting Agent. Read the press release: $MAIA #NSCLC #Biotech #Immunotherapy https://bit.ly/3IG5e3l https://bit.ly/3IG5e3l"
X Link 2025-09-24T14:06Z [---] followers, [---] engagements
"MAIAs Director of Clinical Operations Matthew Failor attended #ESMO2025 meeting with KOLs and oncologists for meaningful discussions about THIO-101 trial expansion and upcoming clinical programs advancing ateganosine (THIO) in #NSCLC. ICYMI: $MAIA https://bit.ly/43uDnKD https://bit.ly/43uDnKD"
X Link 2025-10-24T15:39Z [---] followers, [---] engagements
"MAIA Leadership Continues Insider Buying in [----] and Trial Data Signals Breakout Potential. Read the release: $MAIA https://bit.ly/4a5p1od https://bit.ly/4a5p1od"
X Link 2025-12-11T15:01Z [---] followers, [---] engagements
"NSCLC market poised to nearly double to $68.8B by [----]. MAIAs ateganosine addresses the largest unmet need: patients without actionable mutations or CPI response. Read the release for more information: https://bit.ly/4q6zNzs https://bit.ly/4q6zNzs"
X Link 2026-01-02T14:00Z [---] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing